RT Journal Article
SR Electronic
T1 Prediction and stratification of longitudinal risk for chronic obstructive pulmonary disease across smoking behaviors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.04.23288086
DO 10.1101/2023.04.04.23288086
A1 He, Yixuan
A1 Qian, David C.
A1 Diao, James A.
A1 Cho, Michael H.
A1 Silverman, Edwin K.
A1 Gusev, Alexander
A1 Manrai, Arjun K.
A1 Martin, Alicia R.
A1 Patel, Chirag J.
YR 2023
UL http://medrxiv.org/content/early/2023/04/05/2023.04.04.23288086.abstract
AB Smoking is the leading risk factor for chronic obstructive pulmonary disease (COPD) worldwide, yet many people who never smoke develop COPD. We hypothesize that considering other socioeconomic and environmental factors can better predict and stratify the risk of COPD in both non-smokers and smokers. We performed longitudinal analysis of COPD in the UK Biobank to develop the Socioeconomic and Environmental Risk Score (SERS) which captures additive and cumulative environmental, behavioral, and socioeconomic exposure risks beyond tobacco smoking. We tested the ability of SERS to predict and stratify the risk of COPD in current, previous, and never smokers of European and non-European ancestries in comparison to a composite genome-wide polygenic risk score (PGS). We tested associations using Cox regression models and assessed the predictive performance of models using Harrell’s C index. SERS (C index = 0.770, 95% CI 0.756 to 0.784) was more predictive of COPD than smoking status (C index = 0.738, 95% CI 0.724 to 0.752), pack-years (C index = 0.742, 95% CI 0.727 to 0.756). Compared to the remaining population, individuals in the highest decile of the SERS had hazard ratios (HR) = 7.24 (95% CI 6.51 to 8.05, P < 0.0001) for incident COPD. Never smokers in the highest decile of exposure risk were more likely to develop COPD than previous and current smokers in the lowest decile with HR=4.95 (95% CI 1.56 to 15.69, P=6.65×10−3) and 2.92 (95%CI 1.51 to 5.61, P=1.38×10−3), respectively. In general, the prediction accuracy of SERS was lower in the non-European populations compared to the European evaluation set. In addition to genetic factors, socioeconomic and environmental factors beyond smoking can predict and stratify COPD risk for both non- and smoking individuals. Smoking status is often considered in screening; other non-smoking environmental and non-genetic variables should be evaluated prospectively for their clinical utility.Competing Interest StatementEKS has received grant and travel support from GlaxoSmithKline. MHC has received grant support from GSK, consulting fees from Genentech and AstraZeneca, and speaking fees from Illumina. All other authors declare no competing interests. Funding StatementUK Biobank data was accessed under application number 22881. All participants from the UK Biobank provided written informed consent for anonymized data to be used for research and publication. This work was supported by the Bioinformatics and Integrative Genomics training grant from the National Institutes of Health NHGRI under award number T32HG002295, the National Institutes of Health NIEHS under award number R01ES032470, NIAID under award number R01AI12725003, the National Science Foundation Graduate Research Fellowship under award number DGE1745303 (to Y.H.), and the UK Biobank Early-Career Researcher Award (to Y.H.). We are grateful for the volunteers who participated in the UK Biobank. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank data are available by application via https://www.ukbiobank.ac.uk/.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesUK Biobank data are available by application via https://www.ukbiobank.ac.uk/. PXStools is available for download at https://github.com/yixuanh/PXStools. Weights for the composite polygenic risk score were downloaded from https://www.copdconsortium.org/polygenic-risk-score. https://github.com/yixuanh/PXStools https://www.copdconsortium.org/polygenic-risk-score https://www.ukbiobank.ac.uk/